VASORINIL

VASORINIL

Therapeutic indications

Nasal decongestant.

Dosage and method of use

Adults and children over 12 years: two or three sprays per day for each nostril. Each spray delivers 0.08 ml of product. Do not exceed the recommended dose.

Contraindications

Glaucoma, prostatic hypertrophy, heart disease and severe arterial hypertension, hyperthyroidism, severe renal insufficiency. Subjects with already known hypersensitivity to the components. The drug is contraindicated in children under 12 years of age. In chronic rhinitis, the prolonged use of vasoconstrictors is generally contraindicated.

Side effects

The product can locally cause sensitization phenomena or congestion of the rebound mucosa. For rapid absorption through the inflamed mucous membranes (or the digestive mucosa) systemic effects may occur consisting of arterial hypertension, reflex bradycardia, headache, urination disturbances.

Special warnings

In children over 12 years, the elderly and the first months of pregnancy, the product should only be administered after consulting your doctor. In patients with cardiovascular diseases and especially in hypertensive patients, the use of nasal decongestants must be subjected to the judgment of the physician from time to time. The use, especially if prolonged, of topical products, can cause sensitization phenomena; in this case it is necessary to interrupt the treatment and institute a suitable therapy. In the absence of an appreciable therapeutic response within a few days, consult your doctor: in any case, the treatment cannot be continued for more than 4 days. Strictly adhere to the recommended doses. Vasorinil should not be used orally. Avoid contact with the eyes. The product, if accidentally ingested or if used for a long time in excessive doses, can cause toxic phenomena. It should be kept out of the reach of children as accidental ingestion can cause marked sedation. The expiry date indicated refers to the product in intact packaging, correctly stored.

Pregnancy and breastfeeding

In pregnant women and in very early childhood, the product should be administered in case of real need and under direct medical supervision.

Expiration and retention

None.

Interactions with other drugs

Do not administer the product during or in the two weeks following antidepressant therapy.

Overdose

In this case, arterial hypertension, tachycardia, photophobia, intense headache, chest tightness and, in children, hypothermia and severe depression of the central nervous system with marked sedation may appear, requiring the adoption of adequate emergency measures.

Active principles

100 ml of solution contain: Active ingredient: Tetrizoline hydrochloride 0.10 g

Excipients

Benzalkonium chloride 0.01 g; sodium edetate 0.10 g; dibasic sodium phosphate 0.63 g; monobasic sodium phosphate 0.17 g; sodium chloride 0.500 g; menthol 0.025 g; eucalyptol 0.0075 g; distilled water 97.64 g.